Anderson Wittekind William Sells 20,000 Shares of Renovaro Inc. (NASDAQ:RENB) Stock

Renovaro Inc. (NASDAQ:RENB) major shareholder Anderson Wittekind William sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $1.58, for a total value of $31,600.00. Following the completion of the sale, the insider now directly owns 1,243,499 shares in the company, valued at $1,964,728.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Anderson Wittekind William also recently made the following trade(s):

• On Thursday, June 27th, Anderson Wittekind William sold 14,671 shares of Renovaro stock. The stock was sold at an average price of $1.50, for a total value of $22,006.50.
• On Friday, June 14th, Anderson Wittekind William sold 50,000 shares of Renovaro stock. The shares were sold at an average price of $1.58, for a total value of $79,000.00.

Renovaro Stock Up 16.7 %

Shares of RENB stock opened at $1.75 on Friday. The stock has a fifty day moving average of $1.43 and a 200 day moving average of $2.60. The firm has a market capitalization of $258.14 million, a price-to-earnings ratio of -2.24 and a beta of 0.44. Renovaro Inc. has a 52 week low of $0.39 and a 52 week high of $5.25.

Renovaro (NASDAQ:RENB) last announced its earnings results on Wednesday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter.

Institutional Trading of Renovaro

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Renovaro by 904.0% during the first quarter. Vanguard Group Inc. now owns 3,916,672 shares of the company’s stock valued at $10,379,000 after purchasing an additional 3,526,565 shares in the last quarter. Tidal Investments LLC bought a new position in Renovaro during the 1st quarter valued at approximately $98,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Renovaro in the first quarter worth $46,000. 71.41% of the stock is owned by hedge funds and other institutional investors.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.